CIRM Funded Clinical Trials

A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC


Steven Dubinett
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$11,815,315
Trial Sponsor:
University of California, Los Angeles
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A
Details: 

The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is between one and 10 percent.

To address this devastating condition, UCLA researchers are genetically modifying a patient’s own dendritic cells – key cells of the immune system – to boost their ability to stimulate native T cells - a type of white blood cell - to destroy cancer cells. 

The investigators will combine this cell therapy with the FDA-approved therapy pembrolizumab (better known as Keytruda) a therapeutic that renders cancer cells more susceptible to clearance by the immune system.

Design: 

Dose escalation and expansion.

Goal: 

Determination of maximum tolerated dose and objective response rate at selected dose in lung cancers.